239 related articles for article (PubMed ID: 32974693)
1. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer.
Grova MM; Strassle PD; Navajas EE; Gallagher KK; Ollila DW; Downs-Canner SM; Spanheimer PM
Ann Surg Oncol; 2021 Apr; 28(4):2182-2190. PubMed ID: 32974693
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?
Postlewait LM; Teshome M; DeSnyder SM; Lim B; Kuerer HM; Bedrosian I; Woodward WA; Ueno NT; Lucci A
Ann Surg Oncol; 2020 Nov; 27(12):4603-4612. PubMed ID: 32710271
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
4. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of pathological nodal burden after neoadjuvant chemotherapy in initially cN0-1 breast cancer patients: a dual-center, 10-year survival analysis.
Maimaitiaili A; Fan Z; Zhang J; Wang Y; Shi B; Zheng J; Li G; Zhao Y; Pu S; He J; Qu F; Zhang H
Ther Adv Med Oncol; 2024; 16():17588359241248318. PubMed ID: 38716480
[TBL] [Abstract][Full Text] [Related]
7. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
8. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
Fayanju OM; Ren Y; Greenup RA; Plichta JK; Rosenberger LH; Force J; Suneja G; Devi GR; King TA; Nakhlis F; Hyslop T; Hwang ES
Breast Cancer Res Treat; 2020 Feb; 180(1):207-217. PubMed ID: 31960171
[TBL] [Abstract][Full Text] [Related]
9. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
[TBL] [Abstract][Full Text] [Related]
10. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study.
de Wild SR; Koppert LB; de Munck L; Vrancken Peeters MTFD; Siesling S; Smidt ML; Simons JM
Breast Cancer Res Treat; 2024 Apr; 204(2):277-288. PubMed ID: 38133707
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
15. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database.
Kupstas AR; Hoskin TL; Day CN; Boughey JC; Habermann EB; Hieken TJ
Br J Surg; 2020 Jul; 107(8):1033-1041. PubMed ID: 32057107
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
17. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
[TBL] [Abstract][Full Text] [Related]
19. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
[TBL] [Abstract][Full Text] [Related]
20. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]